Steward Partners Investment Advisory’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
BI
DTC
CAM
MB
WAM
LGM
Steward Partners Investment Advisory's MLTX Position: Q1 2026 in Review
Steward Partners Investment Advisory increased its MoonLake Immunotherapeutics (MLTX) stake by 157% in Q1 2026, buying an estimated $2.47K and bringing the position to 244 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.
Steward Partners Investment Advisory first reported a position in MLTX in Q3 2023 and has held it in 4 quarters since. The position peaked at $11.4K in Q3 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.
- Steward Partners Investment Advisory held 244 shares of MoonLake Immunotherapeutics worth $4.55K as of Q1 2026.
- Steward Partners Investment Advisory bought 149 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.47K.
- MoonLake Immunotherapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3828 holding.
- Steward Partners Investment Advisory first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 4 quarters since.
- Steward Partners Investment Advisory's MoonLake Immunotherapeutics position peaked at $11.4K in Q3 2023.
- 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.
Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.